Safety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits

Poly(lactic-co-glycolic acid) (PLGA) and/or poly(lactic-acid) (PLA) microspheres are important drug delivery systems. This study investigated eye biocompatibility and safety of PLGA/PLA microspheres through intravitreal injection in rabbits. Normal New Zealand rabbits were randomly selected and received intravitreal administration of different doses (low, medium, or high) of PLGA/PLA microspheres and erythropoietin-loaded PLGA/PLA microspheres. The animals were clinically examined and sacrificed at 1, 2, 4, 8, and 12 weeks postadministration, and retinal tissues were prepared for analysis. Retinal reactions to the microspheres were evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end staining and glial fibrillary acidic protein immunohistochemistry. Retinal structure changes were assessed by hematoxylin and eosin staining and transmission electron microscopy. Finally, retinal function influences were explored by the electroretinography test. Terminal deoxynucleotidyl transferase-mediated dUTP nick end staining revealed no apoptotic cells in the injected retinas; immunohistochemistry did not detect any increased glial fibrillary acidic protein expression. Hematoxylin and eosin staining and transmission electron microscopy revealed no micro- or ultrastructure changes in the retinas at different time points postintravitreal injection. The electroretinography test showed no significant influence of scotopic or photopic amplitudes. The results demonstrated that PLGA/PLA microspheres did not cause retinal histological changes or functional damage and were biocompatible and safe enough for intravitreal injection in rabbits for controlled drug delivery.

[1]  H. Kaplan,et al.  Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. , 1975, Journal of immunology.

[2]  W. Foulds,et al.  Vitreal, retinal, and pigment epithelial contribution to the posterior blood-ocular barrier. , 1980, Transactions of the ophthalmological societies of the United Kingdom.

[3]  J. O'Callaghan Assessment of neurotoxicity: use of glial fibrillary acidic protein as a biomarker. , 1991, Biomedical and environmental sciences : BES.

[4]  Y. Ikada,et al.  Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. , 1992, Investigative ophthalmology & visual science.

[5]  J. Kreuter Nanoparticulate systems in drug delivery and targeting. , 1995, Journal of drug targeting.

[6]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[7]  J. Streilein Ocular immune privilege: therapeutic opportunities from an experiment of nature , 2003, Nature Reviews Immunology.

[8]  V. Sinha,et al.  Biodegradable microspheres for protein delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[9]  E. Woldemussie,et al.  Müller cell response to laser‐induced increase in intraocular pressure in rats , 2004, Glia.

[10]  Chen Gai-qi Biodegradable microspheres containing adriamycin in thetreatment of proliferative vitreoretinopathy , 2004 .

[11]  S. Picaud,et al.  Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. , 2005, Molecular vision.

[12]  J. Niederkorn See no evil, hear no evil, do no evil: the lessons of immune privilege , 2006, Nature Immunology.

[13]  Eiji Sakurai,et al.  Drug delivery from ocular implants , 2006, Expert opinion on drug delivery.

[14]  A. Mitra,et al.  Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[15]  R. Apte,et al.  Intravitreal pharmacotherapy: applications in retinal disease. , 2007, Comprehensive ophthalmology update.

[16]  M. Tanito,et al.  Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. , 2007, Investigative ophthalmology & visual science.

[17]  M. J. Moore,et al.  Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. , 2007, Molecular vision.

[18]  J. Cunha-Vaz The blood-ocular barriers: past, present, and future , 2007, Documenta Ophthalmologica.

[19]  B. Kolomiets,et al.  Retinal electrophysiology for toxicology studies: applications and limits of ERG in animals and ex vivo recordings. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[20]  H. Edelhauser,et al.  Barriers to Glaucoma Drug Delivery , 2008, Journal of glaucoma.

[21]  Fei Wu,et al.  Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Rishi Paliwal,et al.  Nanocarriers in ocular drug delivery: an update review. , 2009, Current pharmaceutical design.

[23]  Rachel L. Williams,et al.  Drug delivery systems for the eye , 2009, Expert review of medical devices.

[24]  A. Dick,et al.  Immune mechanisms of intraocular inflammation , 2010 .

[25]  X. Rong,et al.  Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  Marcus Ang,et al.  Biocompatibility and Biodegradation Studies of Subconjunctival Implants in Rabbit Eyes , 2011, PloS one.

[27]  X. Rong,et al.  Effects of erythropoietin-dextran microparticle-based PLGA/PLA microspheres on RGCs. , 2012, Investigative Ophthalmology and Visual Science.

[28]  T. Léveillard,et al.  Taurine Provides Neuroprotection against Retinal Ganglion Cell Degeneration , 2012, PloS one.

[29]  C. R. Zárate-Bladés,et al.  The Living Eye “Disarms” Uncommitted Autoreactive T Cells by Converting Them to Foxp3+ Regulatory Cells following Local Antigen Recognition , 2012, The Journal of Immunology.

[30]  K. Avgoustakis,et al.  Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results. , 2013, Experimental eye research.

[31]  P. Campochiaro,et al.  Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. , 2013, Biomaterials.

[32]  郑俊海,et al.  科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会 , 2014 .

[33]  A. Mitra,et al.  Ocular Drug Delivery , 1990 .